Introduction
============

Non-transfusion and transfusion-dependent thalassemia (NTDT and TDT, respectively) are characterized by imbalanced synthesis of α- and β-globin chains, leading to the formation of unstable α-globin chain/heme aggregates (hemichromes) in erythroid cells. Hemichromes impair the differentiation and survival of erythroid progenitors as well as the lifespan of enucleated red blood cells (RBC).^[@b1-1051835]-[@b6-1051835]^

Both NTDT and TDT patients suffer from iron overload and require chronic iron chelation therapy to prevent major complications, such as liver and heart failure.^[@b5-1051835]-[@b9-1051835]^ The mechanism leading to iron accumulation in organs is different in NTDT *vs*. TDT.^[@b5-1051835],[@b6-1051835],[@b10-1051835],[@b11-1051835]^ In NTDT, iron overload is likely mediated by a variety of factors, including increased erythropoiesis, hypoxia and the contribution of factors such as erythroferrone, which suppresses hepcidin synthesis in the liver.^[@b12-1051835]-[@b16-1051835]^ Because hepcidin functionally inhibits iron egress from cells by binding and internalizing the iron transporter ferroportin in enterocytes, iron absorption is increased under conditions of reduced hepcidin synthesis.^[@b3-1051835],[@b16-1051835]-[@b18-1051835]^ Additionally, in hypoxic conditions, synthesis of molecules responsible for mediating iron absorption (including ferroportin) are increased in the duodenum, further contributing to the iron overload in NTDT.^[@b4-1051835],[@b19-1051835],[@b20-1051835]^ In contrast to NTDT patients, TDT patients require chronic RBC transfusion for survival.^[@b9-1051835],[@b18-1051835],[@b21-1051835]^ Because transfused RBC ultimately undergo senescence and require removal by splenic and liver macrophages and because there is no physiological way of excreting the iron recycled from these cells, continuous infusion of RBC is the primary reason for iron overload in TDT patients.^[@b18-1051835],[@b21-1051835],[@b22-1051835]^

Mouse models of β-thalassemia intermedia (e.g. *Hbb^th3/+^* mice) exhibit ineffective erythropoiesis, anemia and reduced or inappropriately normal hepcidin synthesis, but do not require RBC transfusion for survival, similarly to NTDT patients. Minihepcidins function as hepcidin agonists, target ferroportin, and reduce iron absorption and transferrin saturation.^[@b23-1051835],[@b24-1051835]^ We and others showed that administration of minihepcidins or agents that induce hepcidin expression in *Hbb^th3/+^* mice decreased transferrin saturation, heme synthesis, hemichrome formation, and improved RBC lifespan, anemia, and splenomegaly.^[@b17-1051835],[@b25-1051835]-[@b29-1051835]^ Taken together, these experiments demonstrated the potential benefits of minihepcidins in NTDT. However, it is unclear whether minihepcidins would improve anemia, transfusion requirements, and iron overload in TDT.

Based on the pathophysiology of TDT and the effect of minihepcidins on iron metabolism and erythropoiesis in NTDT, we speculate that minihepcidins may: (i) improve ineffective erythropoiesis; (ii) increase RBC lifespan and reverse anemia; (iii) decrease RBC transfusion requirements (decrease frequency of transfusion); (iv) reverse splenomegaly and extramedullary erythropoiesis; (v) decrease indications for splenectomy; and (vi) reverse iron overload in TDT patients.

Multiple existing mouse models of β-thalassemia intermedia harbor different mutations leading to decreased mouse β-globin genes synthesis, triggering ineffective erythropoiesis and anemia ([Figure 1A-C](#f1-1051835){ref-type="fig"}). However, some animals do not require RBC transfusion for survival, while others produce very few RBC.^[@b30-1051835]-[@b33-1051835]^ For example, *Hbb^th1/th1^* mice carry a homozygous spontaneous deletion of 3.7 Kb containing the β-major gene and 2 Kb of the 5' flanking region, including the promoter ([Figure 1A](#f1-1051835){ref-type="fig"}).^[@b34-1051835]^ *Hbb^th2/+^* mice were created by inserting a neomycin-resistant cassette into exon 2 of the β-major gene such that heterozygotes are mildly anemic while homozygotes die perinatally due to severe anemia ([Figure 1B](#f1-1051835){ref-type="fig"}).^[@b35-1051835]^ *Hbb^th3^*^/+^ mice have one copy of the normal β-globin cluster and an allele with a deletion of both the β-major and β-minor genes ([Figure 1C](#f1-1051835){ref-type="fig"}), resulting in moderate anemia that is not severe enough to require transfusion, a phenotype similar to that of *Hbb^th1/th1^* mice.^[@b36-1051835],[@b37-1051835]^ Homozygous *Hbb^th3/th3^* mice die perinatally, preventing their use as an adult model of TDT.^[@b36-1051835]^

![Genetic makeup of established mouse models of β-thalassemia intermedia and a new model of ß-thalassemia major. (A-C) Mouse models of β-thalassemia Intermedia: (A) *Hbb^th1/th1^*, (B) *Hbb^th2/+^*, (C) *Hbb^th3^*^/+^ and (D) a new mouse model of β-thalassemia major: *Hbb^th1/th2^*. The mouse β-globin locus is represented in the 5' to 3' orientation; for simplicity, only the β-globin genes are indicated; not in scale. LCR: β-globin locus control region; βma: β-globin major gene; βmi: β-globin minor gene; N: neomycin gene. Dotted lines represent DNA deletions.](1051835.fig1){#f1-1051835}

We previously used a transplant model in which fetal liver cells from E13.5-15.5 day *Hbb^th3/th3^* embryos are transplanted into irradiated wildtype (WT) syngeneic mice.^[@b36-1051835]-[@b38-1051835]^ Successful engraftment of *Hbb^th3/th3^* fetal liver cells led to ineffective erythropoiesis and severe anemia resulting in death 3 months after transplantation if the animals were not transfused.^[@b16-1051835],[@b38-1051835],[@b39-1051835]^ This and other models were utilized to study dysregulated iron metabolism in β-thalassemia major.^[@b16-1051835],[@b35-1051835]-[@b39-1051835]^ However, *Hbb^th3/th3^* mice are characterized by such low hemoglobin and RBC production that they make testing drugs, such as minihepcidins that have the potential to modify RBC quality and lifespan and improve ineffective erythropoiesis, complex if not impossible.

To assess the efficacy of minihepcidins in TDT, we generated a new mouse model (*Hbb^th1/th2^*) that closely resembles the human TDT phenotype ([Figure 1D](#f1-1051835){ref-type="fig"}). Our aim was to use combinations of already existing mutations in order to generate a model intermediate in severity to those already in use, in which some RBC are produced although their synthesis is insufficient to support long-term survival in the absence of transfusion. Using these mice, we demonstrate the potential beneficial effect of minihepcidins in mice affected by TDT which were or were not given transfusions.

Methods
=======

Animal models
-------------

*Hbb^th1/th1^* mice (B6.D2-Hbb*^d3th^*/BrkJ stock n. 000996) were crossed with *Hbb^th2/+^* animals (B6.129P2-Hbb*^tm1Unc^*/J stock n. 002204).^[@b34-1051835]-[@b36-1051835]^ All recipient mice were 8- to 12-week old females transgenic for either green fluorescent protein (C57BL/6-Tg(UBC-GFP)30Scha/J)^[@b40-1051835]^ or B6.SJL-*Ptprc^a^ Pepc^b^*/BoyJ (known as Pep Boy). The Pep Boy mice allow us to discriminate between endogenous cells \[which carry the differential *Ptprc^a^* pan-leukocyte marker (commonly known as CD45.1 or Ly5.1)\] from the donor fetal liver cells (which carry the CD45.2 or Ly5. variant); similarly, GFP^+^ donors can be distinguished from GFP- recipient source RBC. Blood samples were analyzed as previously described.^[@b3-1051835],[@b41-1051835]^

Hematopoietic chimeras and genotyping
-------------------------------------

Donor fetal liver cells were harvested from embryos (E13.5-15.5 days) obtained by intercrossing *Hbb^th1/th1^*, *Hbb^th2/+^*, or WT mice. Embryonic genotypes were screened by DNA extraction (KAPA Biosystems, Kapa Mouse Genotyping Kit hotstart, KK7352) and polymerase chain reaction analysis (see *Online Supplementary Tables S1* and *S2*). Fetal liver cells were kept on ice and resuspended in sterile phosphate-buffered saline (ThermoFisher PBS, Ph 7.4, CAT 10010023). To establish bone marrow chimeras, 2.0-5.0x10^6^ cells were injected retro-orbitally into each of the irradiated female recipients. Recipient mice were irradiated with 10 Gy (split dose of 2 × 5 Gy) on the day of transplantation (ISOVOLT Titan E Series X-Ray Generators).

Blood transfusion
-----------------

Transfusion was performed as previously described.^[@b16-1051835]^ Starting 2 months after transplantation, mice were transfused weekly via retro-orbital venous plexus with 300 μL freshly harvested blood from normal healthy C57BL/6 mice or GFP. The first transfusion was delivered at the same time as the first minihepcidin administration. The last transfusion was delivered 1 week before the last minihepcidin injection.

Mouse serum erythroferrone measurement
--------------------------------------

The immunoaffinity liquid chromatography-tandem mass spectrometry assay to quantify total erythroferrone protein levels in mouse serum was developed in-house using surrogate peptide analysis. Briefly, total erythroferrone from 25 μL serum was enriched using a biotinylated mouse anti-erythroferrone antibody (Drakesmith Lab) by diluting serum into 75 μL of phosphate-buffered saline-Tween and incubating with antibody at 30°C for 4 h with interval mixing at 600 rpm. Magnetic streptavidin beads were added and incubated for an additional 30 min with interval mixing at 1200 rpm. The bound erythroferrone protein was then eluted from the beads using hydrochloric acid and processed for digestion using Promega trypsin-LysC enzyme at 37°C overnight. The liquid chromatography-tandem mass spectrometry quantification was carried out by monitoring two unique erythroferrone-specific surrogate peptides (EFQLL-LK and SGSHFSAILLGL) using a standard curve generated with a recombinant mouse erythroferrone-Fc protein construct. Levels were measured with a lower limit of quantification (LLOQ) of 0.25 ng/mL.^[@b42-1051835]-[@b44-1051835]^

Statistics
----------

Bars represent standard deviation (SD). When multiple comparisons were needed, statistical analysis was performed using ordinary one-way or two-way analysis of variance (ANOVA) with the Tukey or Sidak adjustment for multiple comparisons. An unpaired two-tailed Student *t*-test was used for comparisons between two groups. *P* values \<0.05 are considered statistically significant. All data were analyzed using GraphPad Prism version 7 (Microsoft GraphPad Software, La Jolla, CA, USA). Data for WT fetal liver cells are presented as a reference.

Animal study approval
---------------------

All animal studies were conducted under protocols approved by the Institutional Animal Care and Use Committee of The Children's Hospital of Philadelphia.

Results
=======

Generation of a new mouse model of β-thalassemia major or transfusion-dependent thalassemia
-------------------------------------------------------------------------------------------

We hypothesized that intercrossing *Hbb^th1/th1^* and *Hbb^th2/+^* mice ([Figure 1A, B](#f1-1051835){ref-type="fig"}) could generate animals that are able to produce RBC, but with insufficient levels of adult hemoglobin for long-term survival ([Figure 1D](#f1-1051835){ref-type="fig"}). At birth *Hbb^th1/th2^* pups were extremely pale but alive (for up to 8 h) and died despite transfusion (*Online Supplementary Figure S1A*) likely due to irreversible damage associated with the severe hypoxia in late gestation. We then focused on generating mice through transplantation of *Hbb^th1/th2^* fetal liver cells into recipient transgenic animals expressing GFP or Pep Boy mice \[*Hbb^th1/th2^* bone marrow chimeras (*Hbb^th1/th2^*BMC)\] (*Online Supplementary Figures S1B* and *S2A*, B; *Online Supplementary Table S1* and *S2*). The GFP^+^ and the Pep Boy (CD45.1) mice were utilized to monitor the chimerism of circulating RBC over time (GFP^−^ *vs*. GFP^+^ RBC) or bone marrow leukocytes (CD45.2 *vs*. CD45.1) and assess engraftment of donor cells. The resulting models demonstrate the desired phenotype 2 months after transplantation, including production of GFP^−^ RBC or CD45.2 bone marrow leukocytes and anemia (*Online Supplementary Figure S3A*, B, [Figure 2](#f2-1051835){ref-type="fig"}).

![Complete blood count analysis of animals affected by β-thalassemia intermedia or major. (A) Red blood cell (RBC) number, (B) hemoglobin (Hb) levels, (C) reticulocytes (RETIC) count and (D) spleen weight. Bars represent standard deviation. \*\*\*\**P*≤0.001. (E) RBC morphology (shown by Giemsa staining of peripheral blood smears) of wildtype (WT), β-thalassemia intermedia and *Hbb^th1/th2^-BMC* mice.](1051835.fig2){#f2-1051835}

*Hbb^th1/th2^*BMC animals showed features of β-thalassemia major, requiring transfusion for long-term survival
--------------------------------------------------------------------------------------------------------------

Two months after transplantation, analysis of the hematologic parameters indicated that *Hbb^th1/th2^*BMC mice produce few RBC, low hemoglobin levels, but high reticulocyte counts ([Figure 2A-C](#f2-1051835){ref-type="fig"}). *Hbb^th1/th2^*BMC mice showed the largest increase in spleen weight ([Figure 2D](#f2-1051835){ref-type="fig"}). Peripheral blood smears confirmed more severe anisocytosis, poikilocytosis and hypochromasia ([Figure 2E](#f2-1051835){ref-type="fig"}) than in models of NTDT. Because *Hbb^th1/th2^*BMC mice do not require transfusion for survival for up to 4 months after transplantation, we analyzed the effect of minihepcidins in the absence of transfusion. After this period, *Hbb^th1/th2^*BMC mice showed exacerbation of their anemia, incompatible with survival.

Administration of minihepcidins ameliorated red blood cell lifespan, ineffective erythropoiesis, anemia and splenomegaly in untransfused *Hbb^th1/th2^*BMC mice
---------------------------------------------------------------------------------------------------------------------------------------------------------------

*Hbb^th1/th2^*BMC were treated with two doses of minihepcidins, 2.625 mg/kg \[(low dose (MH_L)\] or 5.25 mg/kg \[high dose (MH_H)\] 2 months after transplantation. The experimental design is shown in *Online Supplementary* [Figure 4A, B](#f4-1051835){ref-type="fig"}. The duration of the treatment was selected based on the findings of our previous pharmacokinetic studies.^[@b28-1051835]^ Compared to controls (V- vehicle), administration of minihepcidins improved hematologic parameters in a dose-dependent manner. Using the lowest dose, we observed a trend of improved parameters, with the improvement reaching statistical significance with the highest dose. RBC count and hemoglobin concentration were statistically significantly improved in animals treated with the high dose ([Figure 3A, B](#f3-1051835){ref-type="fig"}). Similarly, reticulocyte count and splenomegaly decreased more in MH_H-treated *Hbb^th1/th2^*BMC mice ([Figure 3C, D](#f3-1051835){ref-type="fig"}). We then focused only on the highest dose. Minihepcidin administration also decreased hemichrome formation ([Figure 3E](#f3-1051835){ref-type="fig"}) and reactive oxygen species production ([Figure 3F](#f3-1051835){ref-type="fig"}). Accordingly, RBC morphology ([Figure 4A](#f4-1051835){ref-type="fig"}) and lifespan ([Figure 4B](#f4-1051835){ref-type="fig"}) improved in MH_H-treated mice, relative to vehicle-treated *Hbb^th1/th2^*BMC mice. Flow cytometric analysis of bone marrow and spleen samples ([Figure 4C](#f4-1051835){ref-type="fig"}) demonstrated improved ineffective erythropoiesis in minihepcidin-treated *Hbb^th1/th2^*BMC mice as the percentage ([Figure 4D, E](#f4-1051835){ref-type="fig"}) of erythroid progenitor cells decreased compared to that of mature RBC.

![The effect of minihepcidin on complete blood count and splenomegaly in *Hbb^th1/th2^*-BMC mice. Administration of a low dose of minihepcidin (MH_L) (2.625 mg/kg) or a high-dose (MH_H) (5.25 mg/kg) to *Hbb^th1/th2^*-BMC mice resulted in dose-dependent increases in (A) red blood cell (RBC) count and (B) hemoglobin (Hb) concentration and decreases in (C) reticulocyte (RETIC) count and (D) spleen weight. Bars represent the standard deviation. \*\*\*\**P*≤0.001, \*\**P*≤0.01. (E) Minihepcidin administration also decreased hemichrome formation. (F) Flow cytometry studies of bone marrow and spleen erythroid populations of *Hbb^th1/th2^*-BMC mice treated with MH_H showed reduced levels of reactive oxygen species. BM: bone marrow; ROS: reactive oxygen species.](1051835.fig3){#f3-1051835}

![The iron-restrictive effect of minihepcidin improved ineffective erythropoiesis in *Hbb^th1/th2^*-BMC mice. Minihepcidin improved (A) red blood cell (RBC) morphology and (B) RBC lifespan \[statistics are determined comparing animals treated with vehicle (V) *vs*. high-dose minihepcidin (MH_H)\]. (C) Minihepcidin also improved erythropoiesis in the bone marrow (BM) and spleen of *Hbb^th1/th2^*-BMC mice. (D, E) Flow activated cell sorting analysis of the percentage of BM (D) and splenic (E) erythroid cells using CD44^+^ and Ter119^+^ cells (n=4-5 animals per group). Results are presented as means ± standard deviation: \*\*\*\**P*≤0.001, \*\**P*≤0.01, \**P*≤0.05.](1051835.fig4){#f4-1051835}

Administration of minihepcidins ameliorated iron overload in untransfused *Hbb^th1/th^*^[@b2-1051835]^BMC mice
--------------------------------------------------------------------------------------------------------------

As erythropoiesis improved in *Hbb^th1/th2^*BMC MH_H-treated mice, we investigated whether minihepcidins had a beneficial effect on endogenous hepcidin synthesis and iron metabolism. *Hbb^th1/th2^*BMC mice treated with vehicle demonstrated a significant increase in serum erythroferrone levels compared to WT animals, but a reduction in these values when treated with MH_H ([Table 1](#t1-1051835){ref-type="table"}, [Figure 5A](#f5-1051835){ref-type="fig"}). Endogenous serum hepcidin concentrations were different between untreated and treated animals ([Figure 5B](#f5-1051835){ref-type="fig"}), but no significant differences were observed in transferrin saturation levels ([Figure 5C](#f5-1051835){ref-type="fig"}). However, serum iron levels decreased significantly in MH_H-treated *Hbb^th1/th2^*BMC mice ([Figure 5D](#f5-1051835){ref-type="fig"}). Moreover, *Hbb^th1/th2^*BMC MH_H-treated mice showed significant reductions of iron by \~33% and \~77% in the liver and spleen, respectively, but not in the kidney (tissue iron content in the kidney not shown). ([Figure 5E, F](#f5-1051835){ref-type="fig"} and *Online Supplementary Figure S5*).

###### 

Serum erythroferrone measurements.

![](1051835.tab1)

![Serum and tissues iron analysis showed improvements in *Hbb^th1/th2^*-BMC mice after treatment with minihepcidin. In a comparison of animals treated with vehicle (V) or high-dose hepcidin (MH_H), (A) serum erythroferrone (ERFE) levels were significantly different, (B) serum hepcidin (HAMP) was decreased, (C) while transferrin saturation did not show significant differences. (D) Serum iron was significantly reduced after MH_H administration. As a result of a decreased erythroid iron uptake, total organ iron content was reduced in the (E) liver and (F) spleen, but not in the kidney (*not shown*). Bars represent the standard deviation. \*\*\*\**P*≤0.001, \*\**P*≤0.01; \**P*≤0.05.](1051835.fig5){#f5-1051835}

Minihepcidin treatment ameliorated ineffective erythropoiesis, reversed splenomegaly, and reduced serum iron and heart iron concentration in transfused *Hbb^th1/th2^BMC* mice
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Compared to *Hbb^th1/th^*^[@b2-1051835]^BMC mice treated with vehicle, blood transfusion in animals treated or not with MH_H (see experimental design in *Online Supplementary Figure S4B*) resulted in increased RBC count and hemoglobin concentration, and decreased reticulocyte count and serum erythropoietin concentration ([Figure 6A-D](#f6-1051835){ref-type="fig"}). Furthermore, flow cytometric analysis of bone marrow and splenic erythroid cells demonstrated that the combination of MH_H and blood transfusion further reduced the total number of erythroid progenitors compared to blood transfusion alone, indicating an improvement of ineffective erythropoiesis (*Online Supplementary Figure S6A-C*).

![Minihepcidin and blood transfusion improved hematologic parameters and reduced serum erythropoietin in *Hbb^th1/th2^*-BMC mice. Administration of minihepcidin resulted in (A) increased red blood cell (RBC) count and (B) hemoglobin (Hb) levels, while (C) reticulocytes (RETIC) numbers were reduced. (D) Serum erythropoietin (EPO) concentration did not show statistical differences. Bars represent standard deviation. \*\*\*\**P*≤0.001, \*\**P*≤0.01. WT: wildtype; FLC: fetal liver cells; V: vehicle; MH_H: high-dose minihepcidin; Bl.Tr: blood transfusion.](1051835.fig6){#f6-1051835}

Transfusion alone in *Hbb^th1/th2^*BMC mice resulted in significantly increased serum hepcidin ([Figure 7A](#f7-1051835){ref-type="fig"}), likely due to suppression of both serum erythropoietin concentration ([Figure 6D](#f6-1051835){ref-type="fig"}) and endogenous erythropoiesis (*Online Supplementary Figure S6*). Administration of MH_H (with and without blood transfusion) had little effect on transferrin saturation ([Figure 7B](#f7-1051835){ref-type="fig"}), but improved serum iron levels ([Figure 7C](#f7-1051835){ref-type="fig"}) in non-transfused *Hbb^th1/th2^*BMC mice. Compared to *Hbb^th1/th2^*BMC mice treated with vehicle alone, transfusion significantly decreased liver iron concentration ([Figure 7D](#f7-1051835){ref-type="fig"}, *Online Supplementary Figure S7*), likely due to the increased levels in serum hepcidin ([Figure 7A](#f7-1051835){ref-type="fig"}), but no further decrease was observed in MH_H-treated transfused *Hbb^th1/th2^*BMC mice.

![Improved iron parameters and splenomegaly in *Hbb^th1/th2^*-BMC mice treated with minihepcidin and blood transfusion. (A) Hepcidin (HAMP) levels increased in the group given blood transfusions (Bl.Tr.) with or without high-dose minihepcidin (MH-H). (B) Transferrin saturation levels were not statistically different in treated or untreated animals. (C) Serum iron levels were decreased in the animals given blood transfusions compared to animals treated with vehicle (V) alone and were similar to those in animals treated with MH-H. (D) Liver iron content was decreased in animals given blood transfusions (with or without MH_H) when compared to animals treated with vehicle and similar to those treated with MH_H alone. (E, F) Total iron content in the heart (E) and spleen (F) was decreased. (G) Spleen weight was almost normalized in MH_H- treated mice, transfused or not. Bars represent the standard deviation. \*\*\*\**P*≤0.001, \*\*\**P*≤0.005, \*\**P*≤0.01; \**P*≤0.05.](1051835.fig7){#f7-1051835}

Appreciable iron deposition in the heart makes our model helpful to study a pathological feature extremely relevant in patients affected by thalassemia major. In particular, when we looked at the iron concentration in the heart, we observed that minihepcidins in combination with a transfusion regimen significantly reduced iron content ([Figure 7E](#f7-1051835){ref-type="fig"}). Furthermore, as minihepicidins enable iron sequestration and reduce ineffective erythropoiesis, we postulate that the decreased erythroid mass also reduces the amount of iron utilized, leading to a relative normalization of transferrin saturation and parenchymal iron deposition. Furthermore, MH_H treatment in transfused *Hbb^th1/th2^*BMC mice decreased total spleen iron ([Figure 7F](#f7-1051835){ref-type="fig"}, *Online Supplementary Figure S7*) and splenomegaly ([Figure 7G](#f7-1051835){ref-type="fig"}), reaching levels similar to those in WT mice. Therefore, administration of minihepcidins may also be beneficial in reducing or preventing splenomegaly and organ-associated iron overload in the presence of blood transfusion.

Discussion
==========

We crossed models of NTDT *Hbb^th1/th1^* with *Hbb^th2/+^* to generate a combination of mutations that decreased synthesis of mouse β-globin genes to mimic TDT. These models exhibit severe anemia, high erythroferrone and low hepcidin levels in the serum, iron overload and succumbed to death due to anemia 4 months after transplantation, mimicking the most severe form of thalassemia in humans. This relatively slow progression to fatal anemia enables this model to be used to study drugs, such as minihepcidins, with the potential to modulate ineffective erythropoiesis in the presence and absence of transfusions.

The administration of a minihepicidin improved RBC morphology, hemichrome formation, and thus the quality of RBC, and reversed splenomegaly, ineffective erythropoiesis, and anemia in *Hbb^th1/th2^*BMC mice, our new model of TDT. Furthermore, iron parameters, such as serum, liver, and spleen iron concentration, were decreased in the minihepcidin-treated *Hbb^th1/th2^*BMC mice. Interestingly, serum erythroferrone levels were decreased, as expected by a reduction in the number of erythroid progenitor cells, while hepcidin level was reduced in comparison to that in untreated mice. This could be explained by the reduction in liver iron concentration, which may prevail over reduced erythroferrone levels on regulating hepcidin expression. When a minihepcidin was combined with transfusion, it further improved splenomegaly, with animals treated in this way showing an average spleen weight similar to that of WT mice. This suggests that, in TDT patients, this approach could further prevent or decrease splenomegaly, thereby reducing the requirement for splenectomy.

Interestingly, in this setting (6 weeks of weekly blood transfusions), we did not observe any effect of the minihepcidin on anemia (seen 6 days after the last blood transfusion). It is possible that our transfusion regimen (rate of administration, 6-week treatment and volume of blood transfused) may have been insufficient to show potential differences associated with the administration of minihepicidins. Alternatively, administration of the minihepicidin may have slightly reduced the life-span of transfused RBC (*Online Supplementary Figure S8*). Future studies will address whether this phenomenon is associated only with this compound or with any drug that activates or mimics hepcidin activity. Looking at the characteristics of this mouse model, different endpoints may be observed in ß-thalassemic patients treated with a similar drug. For instance these animals appear to absorb more iron and produce more reticulocytes compared to humans. In addition, the amount of transfusion was limited (only 6 weeks compared to lifelong treatment in humans) and the regimen of drug administration will likely be different in young and old patients. Nevertheless, our data indicate that minihepicidin administration provides several beneficial effects in combination with transfusion, such as reducing serum and heart iron concentration, while improving ineffective erythropoiesis, and splenomegaly. Based on previous data from thalassemia intermedia mice and now from this new TDT model, we speculate that administration of minihepicidins may reduce or eliminate the requirement for transfusions by enhancing the efficiency of endogenous, more iron-restricted, erythropoiesis in several scenarios: (i) for those NTDT patients who become progressively more transfusion-dependent due to disease progression and (ii) in patients with intermittent transfusion requirements, stabilizing endogenous hemoglobin synthesis sufficiently to avoid transfusion.^[@b4-1051835],[@b5-1051835],[@b45-1051835],[@b46-1051835]^ These potentially beneficial effects of minihepicidins may be further enhanced by combination with drugs that increase RBC synthesis, such as luspatercept or sotatercept.^[@b47-1051835]-[@b50-1051835]^

In conclusion, we generated a new model of TDT that can be utilized to test drugs with the potential to improve ineffective erythropoiesis and anemia. Furthermore, we demonstrate that a minihepicidin has the potential to improve erythropoiesis and iron metabolism in this model, providing pre-clinical proof-of-concept for its use also in β-thalassemic patients affected by forms of anemias more severe than those observed in NTDT.
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